Engineered Cells for Personalized Biomolecule Release

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current protein-based therapeutics have short half-lives and require frequent intravenous or subcutaneous injections, which is inefficient due to poor stability compared to small molecule drugs, and existing cell or gene therapies do not offer therapeutic peptide release tailored to a patient's unique biology or self-administered drug release triggers.

Innovation Solution

Engineering cells via gene therapy to dynamically secrete therapeutic proteins or peptides in response to physiological cues, disease-related molecular signals, or external stimuli, using nucleic acids with specific promoters and response elements, such as those from Guassia princeps or Cypridina noctiluca luciferase, erythropoietin, follicle stimulating hormone, or insulin, to optimize drug delivery.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If protein-based therapeutics are administered via frequent intravenous or subcutaneous injections, then therapeutic levels can be maintained, but treatment efficiency decreases and patient burden increases due to short half-lives and poor stability

Engineering Contradiction:

Improvetherapeutic protein stabilityVSAvoidtreatment frequency

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The therapeutic protein gene is introduced into target cells in advance, enabling the cells to produce and secrete the protein continuously in vivo, eliminating the need for repeated external administrations and maintaining stable therapeutic levels over time

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The engineered cells autonomously produce and secrete the therapeutic protein in response to physiological conditions, making the treatment self-sustaining without requiring continuous external intervention or monitoring

Inventive Principle:

Principle #25Self-service

2Adaptability or versatility

If cell-based therapies are engineered to secrete therapeutic proteins dynamically in response to physiological cues, then treatment is personalized and timely, but device and treatment complexity increases

Engineering Contradiction:

Improvepersonalized drug deliveryVSAvoidgene therapy construct complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The promoter sequence and response element are combined into a single integrated genetic construct that naturally couples the therapeutic protein expression with physiological regulation, eliminating the need for separate control systems while achieving personalized, responsive drug delivery

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

Physiological molecules such as cAMP, calcium ions, or other endogenous signals serve as natural intermediaries that translate cellular physiological states into therapeutic protein expression, providing a bridge between patient biology and treatment response without requiring external monitoring devices

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20220144913A1Personalized and timed release of biomolecules

Publication Date: 2022.05.12 THE GENERAL HOSPITAL CORP

AI summary

Methods and compositions for use in engineering cells to secrete therapeutic biomolecules into the blood stream in vivo in response to an individual's personal biological needs.